CHDI
Listed here are over 1000 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Sbodio JI, Paul BD, Machamer CE, Snyder SH
Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease
Lee CY, Cantle JP, Yang XW
Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis
Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, Teune LK, van Oostrom JC, Guttman M, Dhawan V, Eidelberg D
Metabolic network as a progression biomarker of premanifest Huntington's disease
J Clin Invest
September 2, 2013
123 (9) :4076-88
123 (9) :4076-88
PMID: 23985564
PMCID: 3754266
DOI: 10.1172/JCI69411
Maillard MC, Dominguez C, Gemkow MJ, Krieger F, Park H, Schaertl S, Winkler D, Munoz-Sanjuan I
A label-free LC/MS/MS-based enzymatic activity assay for the detection of genuine caspase inhibitors and SAR development
Winkler D, Beconi M, Toledo-Sherman LM, Prime M, Ebneth A, Dominguez C, Munoz-Sanjuan I
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)
Delmaire C, Dumas EM, Sharman MA, van den Bogaard SJ, Valabregue R, Jauffret C, Justo D, Reilmann R, Stout JC, Craufurd D, Tabrizi SJ, Roos RA, Durr A, Lehericy S
The structural correlates of functional deficits in early huntington`s disease
Lee JM, Galkina EI, Levantovsky RM, Fossale E, Anne Anderson M, Gillis T, Srinidhi Mysore J, Coser KR, Shioda T, Zhang B, Furia MD, Derry J, Kohane IS, Seong IS, Wheeler VC, Gusella JF, MacDonald ME
Dominant effects of the Huntington`s disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategy
Hum Mol Genet
August 15, 2013
22 (16) :3227-38
22 (16) :3227-38
PMID: 23595883
PMCID: PMC3723309
DOI: 10.1093/hmg/ddt176
Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Pérez-Otaño I
Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models
Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, Lee WC
The direct medical costs of Huntington`s disease by stage. A retrospective commercial and Medicaid claims data analysis
Bonner-Jackson A, Long JD, Westervelt H, Tremont G, Aylward E, Paulsen JS, Predict-Hd Investigators, Coordinators of the Huntington Study Group
Cognitive reserve and brain reserve in prodromal Huntington`s disease
Delli Carri A, Onorati M, Castiglioni V, Faedo A, Camnasio S, Toselli M, Biella G, Cattaneo E
Human pluripotent stem cell differentiation into authentic striatal projection neurons
O’Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, Dasso M, Bates GP, Difiglia M, Davidson B, Wanker EE, Marsh JL, Lima CD, Steffan JS, Thompson LM
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation
Chen JY, Wang EA, Cepeda C, Levine MS
Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility
Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ
Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation
Fisher SP, Black SW, Schwartz MD, Wilk AJ, Chen TM, Lincoln WU, Liu HW, Kilduff TS, Morairty SR
Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease
Bari M, Battista N, Valenza M, Mastrangelo N, Malaponti M, Catanzaro G, Centonze D, Finazzi-Agrò A, Cattaneo E, Maccarrone M
In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system
Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P, EU US CTAD Task Force Members
Designing drug trials for Alzheimer`s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force
Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, Track-Hd Investigators
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington`s disease in the TRACK-HD study: analysis of 36-month observational data
Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W
Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease
Parmentier F, Lejeune FX, Neri C
Pathways to decoding the clinical potential of stress response FOXO-interaction networks for Huntington's disease: of gene prioritization and context dependence
Benraiss A, Toner MJ, Xu Q, Bruel-Jungerman E, Rogers EH, Wang F, Economides AN, Davidson BL, Kageyama R, Nedergaard M, Goldman SA
Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease
Wolf RC, Thomann PA, Thomann AK, Vasic N, Wolf ND, Landwehrmeyer GB, Orth M
Brain structure in preclinical Huntington's disease: a multi-method approach
Conforti P, Mas Monteys A, Zuccato C, Buckley NJ, Davidson B, Cattaneo E
In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice
Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, Becker C, Sampaio C, Tobin AJ, Schulman H
8OHdG is not a biomarker for Huntington disease state or progression
Jahanshahi A, Vlamings R, van Roon-Mom WM, Faull RL, Waldvogel HJ, Janssen ML, Yakkioui Y, Zeef DH, Kocabicak E, Steinbusch HW, Temel Y
Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington's disease
Labuschagne I, Jones R, Callaghan J, Whitehead D, Dumas EM, Say MJ, Hart EP, Justo D, Coleman A, Dar Santos RC, Frost C, Craufurd D, Tabrizi SJ, Stout JC, Track-Hd Investigators
Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington`s disease
Beste C, Stock AK, Ness V, Hoffmann R, Lukas C, Saft C
A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data
Liot G, Zala D, Pla P, Mottet G, Piel M, Saudou F
Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites
Rattray I, Smith E, Gale R, Matsumoto K, Bates GP, Modo M
Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD
Lewandowski NM, Bordelon Y, Brickman AM, Angulo S, Khan U, Muraskin J, Griffith EY, Wasserman P, Menalled L, Vonsattel JP, Marder K, Small SA, Moreno H
Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease
Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group
Refining the diagnosis of Huntington disease: the PREDICT-HD study
Dumas EM, van den Bogaard SJ, Hart EP, Soeter RP, van Buchem MA, van der Grond J, Rombouts SA, Roos RA, TRACK-HD investigator group
Reduced functional brain connectivity prior to and after disease onset in Huntington's disease
Brooks SP, Dunnett SB
Cognitive deficits in animal models of basal ganglia disorders
Papp KV, Snyder PJ, Mills JA, Duff K, Westervelt HJ, Long JD, Lourens S, Paulsen JS
Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease
Georgiou-Karistianis N, Gray MA, Dominguez DJf, Dymowski AR, Bohanna I, Johnston LA, Churchyard A, Chua P, Stout JC, Egan GF
Automated differentiation of pre-diagnosis Huntington`s disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study
Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
van den Bogaard SJ, Dumas EM, Hart EP, Milles J, Reilmann R, Stout JC, Craufurd D, Gibbard CR, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA
Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up
Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR
A fully humanized transgenic mouse model of Huntington disease
van Wamelen DJ, Aziz NA, Anink JJ, van Steenhoven R, Angeloni D, Fraschini F, Jockers R, Roos RA, Swaab DF
Suprachiasmatic nucleus neuropeptide expression in patients with Huntington's disease
Read J, Jones R, Owen G, Leavitt BR, Coleman A, Roos RA, Dumas EM, Durr A, Justo D, Say M, Stout JC, Tabrizi SJ, Craufurd D, Track-Hd investigators
Quality of life in Huntington`s disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners